Kymera Therapeutics, Inc. (KYMR) Balance Sheet
KYMR balance sheet, 2025
December 31, 2025 · U.S. dollars$1.74B assets = $163.1M liabilities + $1.58B equity
Both columns are drawn to the same scale: what KYMR owns equals what it owes plus shareholders’ equity. Hover a block for its value.
KYMR financial health
Descriptive bands, not a rating. Fiscal 2025.
KYMR balance sheet trends, 2018–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $44.2M2018 | $1.74B2025 | +69.0%/yr | |
| Total liabilities | $78.7M2018 | $163.1M2025 | +11.0%/yr | |
| Shareholders’ equity | −$34.4M2018 | $1.58B2025 | — | |
| Cash & short-term investments | $41.3M2018 | $848.3M2025 | +54.0%/yr | |
| Total debt | $695,0002018 | $82.3M2025 | +97.8%/yr | |
| Net cash (debt) | $40.6M2018 | $766.0M2025 | +$725.5M | |
| Working capital | $37.1M2018 | $788.0M2025 | +$750.9M | |
| Book value per share | −$0.772018 | $18.722025 | — | |
| Debt / equity | 0.062020 | 0.052025 | −0.01 | |
| Shares outstanding | 44.5M2018 | 84.4M2025 | +9.6%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
KYMR assets
KYMR liabilities and equity
KYMR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
KYMR balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & short-term investments | $848.3M | $488.7M | $374.9M | $407.2M | $442.4M | $296.2M | $92.0M | $41.3M |
| Cash & equivalents | $357.0M | $120.3M | $110.0M | $68.4M | $48.0M | $31.0M | $76.0M | $41.3M |
| Short-term investments | $491.3M | $368.5M | $264.9M | $338.8M | $394.4M | $265.2M | $15.9M | $0 |
| Receivables | $0 | $947,000 | $18.8M | $2.5M | $135,000 | $1.4M | $287,000 | $148,000 |
| Inventory | $0 | $0 | $1 | −$12.2M | −$9.0M | −$163.4M | $0 | $0 |
| Other current assets | $22.9M | $20.6M | $11.7M | $22.0M | $17.7M | $168.1M | $601,000 | $382,000 |
| Total current assets | $871.2M | $510.3M | $405.3M | $419.4M | $451.3M | $302.3M | $92.8M | $41.8M |
| Property, plant & equipment (net) | $85.5M | $97.9M | $101.1M | $22.2M | $21.3M | $20.7M | $22.1M | $2.2M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $771.2M | $362.2M | $61.4M | $152.3M | $125.2M | $162.5M | $0 | $0 |
| Other non-current assets | $14.9M | $7.7M | $7.9M | $9.1M | $8.1M | $1.6M | $1.8M | $199,000 |
| Total assets | $1.74B | $978.0M | $575.8M | $603.1M | $605.9M | $487.2M | $116.7M | $44.2M |
| Liabilities | ||||||||
| Accounts payable | $4.0M | $6.0M | $7.1M | $4.3M | $4.0M | $4.4M | $3.3M | $2.1M |
| Short-term debt | $13.8M | $13.1M | $6.3M | $3.9M | $3.6M | $3.3M | $3.4M | $302,000 |
| Deferred revenue | $22.9M | $13.6M | $37.9M | $35.3M | $61.7M | $92.6M | $23.3M | $2.3M |
| Total current liabilities | $83.2M | $67.8M | $85.7M | $71.3M | $92.5M | $110.6M | $34.6M | $4.7M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $82.3M | $87.8M | $84.7M | $17.3M | $18.0M | $18.0M | $21.2M | $695,000 |
| Other long-term liabilities | $79.9M | $74.6M | $95.1M | $41.6M | $53.7M | $92.7M | $156.5M | $74.0M |
| Total liabilities | $163.1M | $142.4M | $180.8M | $113.0M | $146.3M | $203.3M | $191.1M | $78.7M |
| Shareholders' equity | ||||||||
| Common stock & paid-in capital | $8,000 | $7,000 | $6,000 | $6,000 | $5,000 | $4,000 | — | — |
| Retained earnings (deficit) | −$1.07B | −$754.6M | −$530.8M | −$383.8M | −$229.0M | −$128.8M | −$76.5M | −$35.2M |
| Accumulated other comprehensive income | $1.8M | −$1.5M | −$552,000 | −$4.9M | −$660,000 | −$128,000 | $6,000 | −$224,000 |
| Total shareholders' equity | $1.58B | $835.6M | $395.0M | $490.2M | $459.6M | $283.9M | −$74.4M | −$34.4M |
| Key figures | ||||||||
| Total debt | $82.3M | $87.8M | $84.7M | $17.3M | $18.0M | $18.0M | $21.2M | $695,000 |
| Net cash (debt) | $766.0M | $401.0M | $290.2M | $389.8M | $424.5M | $278.2M | $70.8M | $40.6M |
| Working capital | $788.0M | $442.5M | $319.6M | $348.1M | $358.7M | $191.7M | $58.3M | $37.1M |
| Tangible book value | $1.58B | $835.6M | $395.0M | $490.2M | $459.6M | $283.9M | −$74.4M | −$34.4M |
| Book value per share | $18.72 | $11.14 | $6.77 | $9.09 | $9.58 | $6.37 | −$1.67 | −$0.77 |
| Shares outstanding | 84.4M | 75.0M | 58.4M | 53.9M | 48.0M | 44.6M | 44.5M | 44.5M |
| Current ratio | 10.47 | 7.53 | 4.73 | 5.88 | 4.88 | 2.73 | 2.69 | 8.92 |
| Quick ratio | 10.19 | 7.23 | 4.59 | 5.74 | 4.78 | 2.69 | 2.67 | 8.83 |
| Debt / equity | 0.05 | 0.11 | 0.21 | 0.04 | 0.04 | 0.06 | — | — |
| Equity / assets | 90.6% | 85.4% | 68.6% | 81.3% | 75.9% | 58.3% | −63.8% | −77.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $691.0M | $650.9M | $848.3M | $505.7M | $665.4M | $463.1M | $488.7M | $550.0M | $510.0M | $520.5M | $374.9M | $357.8M |
| Cash & equivalents | $124.5M | $144.1M | $357.0M | $112.9M | $335.8M | $90.0M | $120.3M | $110.7M | $67.6M | $93.5M | $110.0M | $81.1M |
| Short-term investments | $566.5M | $506.8M | $491.3M | $392.7M | $329.6M | $373.2M | $368.5M | $439.3M | $442.3M | $427.0M | $264.9M | $276.8M |
| Receivables | $20.0M | $0 | $0 | $0 | $40.0M | $20.0M | $947,000 | $1.3M | $1.7M | $2.0M | $18.8M | $3.8M |
| Inventory | −$5.8M | $0 | $0 | $0 | $0 | $0 | $0 | −$1.3M | $0 | $1 | $1 | $0 |
| Other current assets | $32.1M | $26.5M | $22.9M | $22.6M | $22.9M | $17.8M | $20.6M | $18.7M | $13.8M | $14.7M | $11.7M | $14.1M |
| Total current assets | $737.3M | $677.4M | $871.2M | $528.3M | $728.3M | $501.0M | $510.3M | $568.7M | $525.4M | $537.3M | $405.3M | $375.7M |
| Property, plant & equipment (net) | $81.1M | $83.4M | $85.5M | $88.1M | $94.6M | $95.9M | $97.9M | $99.3M | $100.4M | $98.7M | $101.1M | $91.1M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $813.9M | $894.7M | $771.2M | $473.1M | $297.6M | $312.3M | $362.2M | $361.0M | $192.4M | $224.4M | $61.4M | $77.0M |
| Other non-current assets | $13.2M | $13.5M | $14.9M | $12.6M | $10.5M | $9.1M | $7.7M | $5.8M | $7.7M | $7.9M | $7.9M | $8.6M |
| Total assets | $1.65B | $1.67B | $1.74B | $1.10B | $1.13B | $918.3M | $978.0M | $1.03B | $826.0M | $868.3M | $575.8M | $552.4M |
| Liabilities | ||||||||||||
| Accounts payable | $8.9M | $12.8M | $4.0M | $5.5M | $5.8M | $10.3M | $6.0M | $6.5M | $6.5M | $6.8M | $7.1M | $5.0M |
| Short-term debt | $17.4M | $13.7M | $13.8M | $13.7M | $13.7M | $13.2M | $13.1M | $12.9M | $12.4M | $9.9M | $6.3M | $3.6M |
| Deferred revenue | — | — | $22.9M | $23.3M | $40.0M | $11.5M | $13.6M | $20.0M | $19.3M | $22.6M | $37.9M | $27.4M |
| Total current liabilities | $75.0M | $62.6M | $83.2M | $71.6M | $87.5M | $59.0M | $67.8M | $66.5M | $62.1M | $56.1M | $85.7M | $63.2M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $78.6M | $80.5M | $82.3M | $84.0M | $85.7M | $86.3M | $87.8M | $88.2M | $88.2M | $87.0M | $84.7M | $80.8M |
| Other long-term liabilities | $64.9M | $66.7M | $79.9M | $84.2M | $72.0M | $73.1M | $74.6M | $75.4M | $79.0M | $100.9M | $95.1M | $93.7M |
| Total liabilities | $139.9M | $129.4M | $163.1M | $155.8M | $159.6M | $132.1M | $142.4M | $141.9M | $141.1M | $157.0M | $180.8M | $156.8M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $8,000 | $8,000 | $8,000 | $7,000 | $7,000 | $7,000 | $7,000 | $7,000 | $6,000 | $6,000 | $6,000 | $6,000 |
| Retained earnings (deficit) | −$1.20B | −$1.14B | −$1.07B | −$979.0M | −$896.8M | −$820.2M | −$754.6M | −$683.9M | −$621.4M | −$579.3M | −$530.8M | −$516.4M |
| Accumulated other comprehensive income | −$7.2M | −$4.2M | $1.8M | $1.5M | $279,000 | −$58,000 | −$1.5M | $1.9M | −$2.1M | −$1.8M | −$552,000 | −$2.5M |
| Total shareholders' equity | $1.51B | $1.54B | $1.58B | $946.3M | $971.5M | $786.2M | $835.6M | $892.9M | $684.9M | $711.2M | $395.0M | $395.5M |
| Key figures | ||||||||||||
| Total debt | $82.2M | $80.5M | $82.3M | $84.0M | $85.7M | $86.3M | $87.8M | $88.2M | $88.2M | $87.0M | $84.7M | $80.8M |
| Net cash (debt) | $608.8M | $570.5M | $766.0M | $421.7M | $579.7M | $376.8M | $401.0M | $461.7M | $421.8M | $433.5M | $290.2M | $277.0M |
| Working capital | $662.3M | $614.8M | $788.0M | $456.7M | $640.8M | $442.0M | $442.5M | $502.2M | $463.3M | $481.1M | $319.6M | $312.5M |
| Tangible book value | $1.51B | $1.54B | $1.58B | $946.3M | $971.5M | $786.2M | $835.6M | $892.9M | $684.9M | $711.2M | $395.0M | $395.5M |
| Book value per share | $15.37 | $15.79 | $18.72 | $10.84 | $12.08 | $9.81 | $10.45 | $11.73 | $9.37 | $10.05 | $6.75 | $6.77 |
| Shares outstanding | 98.2M | 97.5M | 84.4M | 87.3M | 80.4M | 80.1M | 80.0M | 76.1M | 73.1M | 70.8M | 58.5M | 58.4M |
| Current ratio | 9.83 | 10.81 | 10.47 | 7.38 | 8.32 | 8.49 | 7.53 | 8.55 | 8.45 | 9.57 | 4.73 | 5.95 |
| Quick ratio | 9.48 | 10.39 | 10.19 | 7.07 | 8.06 | 8.19 | 7.23 | 8.29 | 8.23 | 9.31 | 4.59 | 5.72 |
| Debt / equity | 0.05 | 0.05 | 0.05 | 0.09 | 0.09 | 0.11 | 0.11 | 0.10 | 0.13 | 0.12 | 0.21 | 0.20 |
| Equity / assets | 91.7% | 92.2% | 90.6% | 85.9% | 85.9% | 85.6% | 85.4% | 86.3% | 82.9% | 81.9% | 68.6% | 71.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.
KYMR financial position
At the end of fiscal 2025 (December 31, 2025), Kymera Therapeutics had total assets of $1.7 billion (up 78.2% from a year earlier), total liabilities of $163.1 million and shareholders' equity of $1.6 billion. It held $848.3 million in cash and short-term investments against $82.3 million of debt, a net cash position of $766.0 million. Its current ratio was 10.47. In the latest quarter (ended June 30, 2026) total assets were $1.6 billion and equity $1.5 billion.
Related: KYMR income statement, KYMR cash flow statement, KYMR key metrics. See the KYMR stock overview for the latest quote and news.
KYMR balance sheet FAQ
What are Kymera Therapeutics's total assets?
Kymera Therapeutics reported total assets of $1.7 billion at the end of fiscal 2025 (December 31, 2025), compared with $978.0 million a year earlier.
How much debt does Kymera Therapeutics have?
Kymera Therapeutics had $82.3 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.05.
How much cash does Kymera Therapeutics have?
Kymera Therapeutics held $848.3 million in cash and short-term investments at the end of fiscal 2025; with $82.3 million of debt that is net cash of $766.0 million.
What is Kymera Therapeutics's book value?
Kymera Therapeutics's shareholders' equity (book value) was $1.6 billion at the end of fiscal 2025, or $18.72 per share.
What is Kymera Therapeutics's current ratio?
Kymera Therapeutics had current assets of $871.2 million and current liabilities of $83.2 million, a current ratio of 10.47 (it can cover its short-term obligations).